Weight gain or plateau on GLP-1 therapy often reflects one of several mechanisms: inadequate dosing for individual receptor sensitivity, tolerance development over time, compensatory eating behavior once appetite suppression wanes, or concurrent metabolic changes unrelated to the medication
While adding medications to potent GLP-1 agonists requires caution, several combinations are commonly discussed in the research community
The Athlete Dilemma: Banned But Widely Used WADA Prohibition Status: BPC-157, TB-500, and most peptides are prohibited at all times under: S0 Category: Non-Approved Substances S2 Category: Peptide Hormones and Growth Factors Consequences for athletes: Positive test = 2-4 year ban Career-ending for professionals Loss of medals, titles, endorsements But Athletes Are Using Anyway Why
This suggests that the supplement isn't just floating around in the blood
Acknowledgements Not applicable Funding This study was supported by the Funding by Science and Technology Projects in Guangzhou (Grant Number: 202201020081)
BPC-157 has been reported to upregulate VEGFR2 (vascular endothelial growth factor receptor 2) and activate the Akt-eNOS pathway, which raises nitric oxide production in blood-vessel walls (Hsieh et al., Journal of Molecular Medicine, 2017